Clinical Trials Search

As a clinical trial candidate at Methodist, you’re offered unique access to new drugs and technology being studied to improve patient outcomes.
Filter by Disease or Condition
Showing 41-45 results of 45
Sarcoma

Servier (IRIS) - CL3-95031-007

Official Title: A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen
Study Purpose: To assess how well the drug Ivosidenib works against chondrosarcoma
Status: Recruiting
Cardiovascular

SOLVE-CRT

Official Title: Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients (SOLVE CRT)
Study Purpose: This study is a prospective, multi-center, randomized, controlled, double blinded, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy.
Status: Active, Not Recruiting
Urinary Cancer

SWOG / S1802

Official Title: Comparing the Treatment Outcome of Standard Systemic Therapy Only versus Standard Systemic Therapy in Combination with Either Surgery or Radiation Therapy, for Patients with Advanced Prostate Cancer
Study Purpose: To compare the effects, good and/or bad, of adding prostate removal surgery or radiation therapy to standard therapy which is used to treat prostate cancer.
Status: Recruiting
Cardiovascular

V-INTERVENTION

Official Title: Evaluation of inclisiran versus placebo for the prevention of major adverse cardiovascular and limb events in patients undergoing percutaneous coronary intervention or peripheral endovascular intervention.
Study Purpose: The purpose is to demonstrate superiority of inclisiran (LEQVIO) compared to placebo on lowering total (first and subsequent) major adverse cardiovascular and limb events after coronary or peripheral endovascular revascularization.
Status: Recruiting
Cardiovascular

ZENITH

Official Title: Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Study Purpose: To evaluate whether zilebesiran versus placebo reduces the risk of CV death, nonfatal MI, nonfatal stroke, or HF events
Status: Available